4 completed, 1 recruiting, 1 withdrawn. 2 Phase 2, 2 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Pemoline: new trials by email Literature Review of Pemoline trials Research Report on Pemoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate Clomiphene Citrate., Pioglitazone (PIO) + Clomiphene citrate - Infertility Treatment, Pregnancy Rates | Phase 4 | Recruiting | PAEC General Hospital, Islamabad | 62 | 2026-03-01 | 2026-03-10 |
| Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer Endometrin® plus Progesterone in Oil (PIO), Progesterone in Oil (PIO) Only - Infertility | Phase 4 | Completed | Shady Grove Fertility Reproductive Science Center | 1139 | 2014-10-01 | 2018-08-02 |
| Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes Placebo / Teneli (Teneligliptin) + pio (pioglitazone), Teneli / Teneli + pio - Type 2 Diabetes Mellitus | Phase 3 | Completed | Tanabe Pharma Corporation | 204 | 2009-12-01 | 2026-01-05 |
| Fracture Risk With Thiazolidinediones TZD only (RSG or PIO or troglitazone), TZD + spironolactone, TZD + amiloride - Fractures, Bone, Type II Diabetes | Completed | GlaxoSmithKline | 98483 | 2009-05-01 | 2017-05-30 | |
| Pemoline in the Treatment of Stimulant Dependence - 5 Pemoline - Cocaine-Related Disorders | Phase 2 | Withdrawn | National Institute on Drug Abuse (NIDA) | 1996-06-01 | 2017-01-12 | |
| Pemoline for Cocaine Abuse - 7 Pemoline - Cocaine-Related Disorders | Phase 2 | Completed | Yale University | 1994-09-01 | 2016-12-15 |
Cocaine-Related Disorders (2) · Diabetes Mellitus, Type 2 (2) · Fractures, Bone (1) · Infertility (1) · Insulin Resistance (1)
GlaxoSmithKline (1) · National Institute on Drug Abuse (NIDA) (1) · PAEC General Hospital, Islamabad (1) · Shady Grove Fertility Reproductive Science Center (1) · Tanabe Pharma Corporation (1) · Yale University (1)
United States (2) · Japan (1) · Pakistan (1)
Kazuoki Kondo, MD (1) · Musarat Ashraf, MBBS,FCPS (1) · Takashi Kadowaki, Professor (1) · Thomas R Kosten, M.D. (1) · Walter Ling, M.D. (1)
PMID 24205974, PMID 24843712, PMID 29338855, PMID 33992421
P50DA009250 (1)